dasiglucagon

Dasiglucagon is a glucagon analog and peptide hormone analog used as an emergency treatment for severe hypoglycemia (very low blood sugar) in adults and children aged 6 years and older with diabetes. It acts as an agonist at the glucagon receptor, primarily in the liver, where it stimulates glycogen breakdown (glycogenolysis) and glucose production (gluconeogenesis), leading to increased blood glucose levels. Dasiglucagon consists of 29 amino acids with seven substitutions compared to endogenous glucagon, improving its stability. It is administered subcutaneously and marketed under the brand name Zegalogue. The drug was developed by Zealand Pharma and received FDA approval in March 2021 for use in patients six years of age or older[3][5][6][7].

Brand names

ZegalogueZegalogue AutoinjectorZegalogue Prefilled Syringe

Other names

dasiglucagon